New hope for stubborn GIST: experimental drug DCC-2618 enters safety testing
Disease control
Not yet recruiting
This early-stage study tests the safety of an experimental drug called DCC-2618 in 10 people with advanced gastrointestinal stromal tumor (GIST) that has not responded to or cannot tolerate at least three prior treatments. The main goal is to see what side effects occur. This is …
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC